Cynthia Anderson
Fortuna: 8 065 $ al 31/05/2026
Fortuna: 8 065 $ al 31/05/2026
Cynthia L.
Anderson formerly worked at Alnylam Pharmaceuticals, Inc., as Chief Accounting Officer from 2019 to 2023 and Vistagen Therapeutics, Inc., as Chief Financial Officer from 2023 to 2025.
Ms. Anderson received her undergraduate degree from the University of Connecticut and graduate degree from The University of Texas at Dallas.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 16/07/2025 | 12.801 ( 0,03 % ) | 8 065 $ | 31/05/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
| VISTAGEN THERAPEUTICS, INC. | Director Financiero/CFO | 15/09/2025 |
| ALNYLAM PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 01/01/2023 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
University of Connecticut
University of Connecticut Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Texas at Dallas
The University of Texas at Dallas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
VistaGen Therapeutics, Inc.
VistaGen Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops central nervous system therapies | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.